312 related articles for article (PubMed ID: 22954303)
21. miRNA-205 targets VEGFA and FGF2 and regulates resistance to chemotherapeutics in breast cancer.
Hu Y; Qiu Y; Yagüe E; Ji W; Liu J; Zhang J
Cell Death Dis; 2016 Jun; 7(6):e2291. PubMed ID: 27362808
[TBL] [Abstract][Full Text] [Related]
22. MicroRNA-218 Increases the Sensitivity of Bladder Cancer to Cisplatin by Targeting Glut1.
Li P; Yang X; Cheng Y; Zhang X; Yang C; Deng X; Li P; Tao J; Yang H; Wei J; Tang J; Yuan W; Lu Q; Xu X; Gu M
Cell Physiol Biochem; 2017; 41(3):921-932. PubMed ID: 28222430
[TBL] [Abstract][Full Text] [Related]
23. MiR-31 regulates the cisplatin resistance by targeting Src in gallbladder cancer.
Li M; Chen W; Zhang H; Zhang Y; Ke F; Wu X; Zhang Y; Weng M; Liu Y; Gong W
Oncotarget; 2016 Dec; 7(50):83060-83070. PubMed ID: 27825112
[TBL] [Abstract][Full Text] [Related]
24. Differential expression of the miR-17-92 cluster and miR-17 family in breast cancer according to tumor type; results from the Norwegian Women and Cancer (NOWAC) study.
Moi L; Braaten T; Al-Shibli K; Lund E; Busund LR
J Transl Med; 2019 Oct; 17(1):334. PubMed ID: 31581940
[TBL] [Abstract][Full Text] [Related]
25. Genomic profiling of microRNAs in bladder cancer: miR-129 is associated with poor outcome and promotes cell death in vitro.
Dyrskjøt L; Ostenfeld MS; Bramsen JB; Silahtaroglu AN; Lamy P; Ramanathan R; Fristrup N; Jensen JL; Andersen CL; Zieger K; Kauppinen S; Ulhøi BP; Kjems J; Borre M; Orntoft TF
Cancer Res; 2009 Jun; 69(11):4851-60. PubMed ID: 19487295
[TBL] [Abstract][Full Text] [Related]
26. miRNA signature associated with outcome of gastric cancer patients following chemotherapy.
Kim CH; Kim HK; Rettig RL; Kim J; Lee ET; Aprelikova O; Choi IJ; Munroe DJ; Green JE
BMC Med Genomics; 2011 Nov; 4():79. PubMed ID: 22112324
[TBL] [Abstract][Full Text] [Related]
27. MicroRNA expression signatures of bladder cancer revealed by deep sequencing.
Han Y; Chen J; Zhao X; Liang C; Wang Y; Sun L; Jiang Z; Zhang Z; Yang R; Chen J; Li Z; Tang A; Li X; Ye J; Guan Z; Gui Y; Cai Z
PLoS One; 2011 Mar; 6(3):e18286. PubMed ID: 21464941
[TBL] [Abstract][Full Text] [Related]
28. DNA Methylation of miR-7 is a Mechanism Involved in Platinum Response through
Vera O; Jimenez J; Pernia O; Rodriguez-Antolin C; Rodriguez C; Sanchez Cabo F; Soto J; Rosas R; Lopez-Magallon S; Esteban Rodriguez I; Dopazo A; Rojo F; Belda C; Alvarez R; Valentin J; Benitez J; Perona R; De Castro J; Ibanez de Caceres I
Theranostics; 2017; 7(17):4118-4134. PubMed ID: 29158814
[TBL] [Abstract][Full Text] [Related]
29. LncRNA MST1P2/miR-133b axis affects the chemoresistance of bladder cancer to cisplatin-based therapy via Sirt1/p53 signaling.
Chen J; Li Y; Li Z; Cao L
J Biochem Mol Toxicol; 2020 Apr; 34(4):e22452. PubMed ID: 32052927
[TBL] [Abstract][Full Text] [Related]
30. MicroRNA Expression Profiles in Human Samples and Cell Lines Revealed Nine miRNAs Associated with Cisplatin Resistance in High-Grade Serous Ovarian Cancer.
Flores-Colón M; Rivera-Serrano M; Reyes-Burgos VG; Rolón JG; Pérez-Santiago J; Marcos-Martínez MJ; Valiyeva F; Vivas-Mejía PE
Int J Mol Sci; 2024 Mar; 25(7):. PubMed ID: 38612604
[TBL] [Abstract][Full Text] [Related]
31. Benzyl isothiocyanate suppresses IGF1R, FGFR3 and mTOR expression by upregulation of miR-99a-5p in human bladder cancer cells.
Lin JF; Tsai TF; Lin YC; Chen HE; Chou KY; Hwang TI
Int J Oncol; 2019 Jun; 54(6):2106-2116. PubMed ID: 30942430
[TBL] [Abstract][Full Text] [Related]
32. MiR-193b Mediates CEBPD-Induced Cisplatin Sensitization Through Targeting ETS1 and Cyclin D1 in Human Urothelial Carcinoma Cells.
Lin SR; Yeh HC; Wang WJ; Ke HL; Lin HH; Hsu WC; Chao SY; Hour TC; Wu WJ; Pu YS; Huang AM
J Cell Biochem; 2017 Jun; 118(6):1563-1573. PubMed ID: 27918099
[TBL] [Abstract][Full Text] [Related]
33. Maspin enhances cisplatin chemosensitivity in bladder cancer T24 and 5637 cells and correlates with prognosis of muscle-invasive bladder cancer patients receiving cisplatin based neoadjuvant chemotherapy.
Chen J; Wang L; Tang Y; Gong G; Liu L; Chen M; Chen Z; Cui Y; Li C; Cheng X; Qi L; Zu X
J Exp Clin Cancer Res; 2016 Jan; 35():2. PubMed ID: 26733306
[TBL] [Abstract][Full Text] [Related]
34. Chemotherapeutics-induced Oct4 expression contributes to drug resistance and tumor recurrence in bladder cancer.
Lu CS; Shieh GS; Wang CT; Su BH; Su YC; Chen YC; Su WC; Wu P; Yang WH; Shiau AL; Wu CL
Oncotarget; 2017 May; 8(19):30844-30858. PubMed ID: 27244887
[TBL] [Abstract][Full Text] [Related]
35. An Oncofetal Glycosaminoglycan Modification Provides Therapeutic Access to Cisplatin-resistant Bladder Cancer.
Seiler R; Oo HZ; Tortora D; Clausen TM; Wang CK; Kumar G; Pereira MA; Ørum-Madsen MS; Agerbæk MØ; Gustavsson T; Nordmaj MA; Rich JR; Lallous N; Fazli L; Lee SS; Douglas J; Todenhöfer T; Esfandnia S; Battsogt D; Babcook JS; Al-Nakouzi N; Crabb SJ; Moskalev I; Kiss B; Davicioni E; Thalmann GN; Rennie PS; Black PC; Salanti A; Daugaard M
Eur Urol; 2017 Jul; 72(1):142-150. PubMed ID: 28408175
[TBL] [Abstract][Full Text] [Related]
36. MiR-199a-3p enhances breast cancer cell sensitivity to cisplatin by downregulating TFAM (TFAM).
Fan X; Zhou S; Zheng M; Deng X; Yi Y; Huang T
Biomed Pharmacother; 2017 Apr; 88():507-514. PubMed ID: 28126676
[TBL] [Abstract][Full Text] [Related]
37. A common MicroRNA signature consisting of miR-133a, miR-139-3p, and miR-142-3p clusters bladder carcinoma in situ with normal umbrella cells.
Jia AY; Castillo-Martin M; Domingo-Domenech J; Bonal DM; Sánchez-Carbayo M; Silva JM; Cordon-Cardo C
Am J Pathol; 2013 Apr; 182(4):1171-9. PubMed ID: 23410519
[TBL] [Abstract][Full Text] [Related]
38. Recovery of miR-139-5p in Ovarian Cancer Reverses Cisplatin Resistance by Targeting C-Jun.
Jiang Y; Jiang J; Jia H; Qiao Z; Zhang J
Cell Physiol Biochem; 2018; 51(1):129-141. PubMed ID: 30439707
[TBL] [Abstract][Full Text] [Related]
39. microRNA expression profile in a large series of bladder tumors: identification of a 3-miRNA signature associated with aggressiveness of muscle-invasive bladder cancer.
Pignot G; Cizeron-Clairac G; Vacher S; Susini A; Tozlu S; Vieillefond A; Zerbib M; Lidereau R; Debre B; Amsellem-Ouazana D; Bieche I
Int J Cancer; 2013 Jun; 132(11):2479-91. PubMed ID: 23169479
[TBL] [Abstract][Full Text] [Related]
40. Upregulated microRNA-193a-3p is responsible for cisplatin resistance in CD44(+) gastric cancer cells.
Lee SD; Yu D; Lee DY; Shin HS; Jo JH; Lee YC
Cancer Sci; 2019 Feb; 110(2):662-673. PubMed ID: 30485589
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
